Calculating the odds of winning a drug war

If winning the drug war means removing all access to illegal drugs then the odds of victory are close to zero. Supply‑side enforcement in the U.S. is unreliable. It fails to reduce drug availability or overall rates of addiction. Drugs are too profitable, too easy to smuggle, and too easy and cheap to replace in the event of captured shipments or arrests of smugglers. Smugglers are also easy to replace.

Under prohibition drug scheduling and enforcement priorities are driven by law enforcement, not health agencies, and not by scientific evidence that might otherwise eliminate punitive, culturalized, racialized, and ineffective efforts criminalizing addiction or use of a drug. Addiction is a human health problem, not a military target.

Enormous social costs are associated with prohibition strategies. There is no reliable estimate of the number of drug war related deaths that have occurred since President Richard M. Nixon declared his war on drugs in 1971 because no country retains the statistics for fatalities related to drug wars.

Despite lacking certain vital statistics drug wars promote increases in state corruption as well as producing drug crimes that lead to bloody extra‑judicial killings. Community disruptions originate with crime syndicates fighting over drug territories while inflicting their self-made justice onto their syndicate members or other people who betray their trust. Drug enforcement funding in the U.S. that began in 1981 with $1 billion increased to roughly $10 billion in the mid‑1990s while cocaine and heroin remained widely available and cheaper than before.

Recent U.S. military involvement in Ecuador’s drug enforcement has escalated to become joint operations targeting alleged “narco‑terrorist” groups with lethal force. Ecuador’s newly elected 35-year-old president, Daniel Noboa, equates organized crime with terrorism to justify military solutions over policing or social policy. He approved a military approach by the U.S. as a way to counter drug cartels in his country.

After a 2025 election that was too close for his own comfort, President Noboa concluded his political future will be secured by being tough on crime. The U.S. attack on Ecuadorian drug smugglers represents a unique political opportunity. Using drugs as an excuse he has suspended civil liberties in key regions of Ecuador and hired U.S. mercenary Erik Prince as his security consultant. Among the suspended civil liberties are citizens’ rights involving warrantless home searches, militarization of domestic policing, freedom of movement and assembly, protections against arbitrary detention, judicial oversight of security operations, and the arbitrary labeling of local gangs as terrorist organizations. Ecuador has begun construction of a high‑security El Salvador-style prison that will one day enable mass detention of prisoners minus any due process of law.

Problems occur with attempts to wipe out cartels. The most likely result of a war on cartels is the ongoing creation of new cartels. New cartels will adapt to new circumstances. Syndicates will continue to survive by using more sophisticated and less detectable smuggling strategies. Any progress made in taking on Ecuador’s cartels or those of any other country will be fleeting. Where there is a drug demand there will be a supply.

If winning a drug war means creating a huge enforcement bureaucracy that fails to eliminate most illegal drug use while providing a steady job and lifetime benefits to its federal and state employees then their jobs and pensions become the victory rather than that of limiting crime. There are no other reliable incentives for prohibitionists to win a drug war. Despite a decades long enforcement strategy an estimated 1.5 million Americans still have continuing access to cocaine no matter what the government does to stop it. Drug enforcement devolves into an ineffective and endless stalemate.

Drug enforcement propaganda depicting drug war successes can overstate the success. The contraband displayed by Attorney General Pam Bondi in a 2025 news release is exceptional in its size and potency, however the odds the drug enforcement agents seen in AG Bondi’s video will ever again be involved in a bust as large or larger are basically zilch. Large scale busts are rare.

Public health approaches to drugs consistently outperform punitive ones because there is a health focus on reducing a person’s physical and mental demand for the drug. If a medical cure for addiction emerges within the next few years it will make current drug treatment facilities medically obsolete. Thirty-five cents of every dollar the U.S. spends on drug enforcement goes to drug treatment that can fail to fully suppress physical or mental cravings for a drug. The most effective drug treatments offer a legal and medically prescribed drug substitute for the addictive substance. There is evidence that psychedelics can help reduce drug cravings, but access to psychedelics is difficult for many people because the drugs are currently being listed and prohibited on Schedule 1 of the controlled substances list. The scheduling list continues to grow as more chemical variations of listed drugs are created or discovered.

Winning the U.S. government’s war on certain drugs means that many people are foregoing effective medical remedies simply because a few bad actors can’t handle their drugs and a host of politicians fails to understand drugs. If the same set of rules were applied to owning automobiles no one would be allowed to drive — think of the children. What remains is a largely ineffective drug war industrial complex coupled with an unwillingness to move forward by implementing better health measures and fewer Kafkaesque bureaucracies.

This entry was posted in Servetus. Bookmark the permalink.

19 Responses to Calculating the odds of winning a drug war

  1. Servetus says:

    Sara Carter is the new Drug Czarina (Director of ONDCP). She is a former journalist and Fox News contributor who has covered drug smuggling stories from Latin America and the Middle East. Carter was assigned the directorship of the ONDCP on January 6, 2026, and she is pushing religion as the way to win the drug war. She says she wants to make faith central to the strategy, as if it hasn’t been tried before:

    YouTube: Trump Administration Makes Faith Central in Strategy to Combat Illicit Drugs

  2. Servetus says:

    New opioid discovery DFNZ has effective pain relief but does not cause respiratory depression or tolerance:

    1-Apr-2026 — Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder … the team observed the new drug’s effect in laboratory animals. They showed that it has high pain-relieving effects without causing respiratory depression, tolerance or other indicators of potential for addiction in humans.

    “Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”

    The team investigated formulations of an understudied class of synthetic opioid compounds, known as nitazenes. Nitazenes selectively engage mu-opioid receptors, primary targets for opioid drugs in the brain and peripheral nervous system. However, nitazenes had been shelved in the 1950s due to their excessive potency. The scientific team revisited this class of compounds with a focus on harnessing their selectivity for the mu opioid receptor and engineering new nitazenes with a safer pharmacological profile.

    “Our goal was to study the profile, or pharmacology, of these drugs,” said Michael Michaelides, Ph.D., senior author and NIDA investigator. “We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations.”

    That investigation revealed DFNZ, another opioid dubbed a “superagonist” for its extremely high efficacy at the mu opioid receptor. […]

    At preclinical therapeutic doses, DFNZ produced a moderate and sustained increase in brain oxygen rather than depressing respiration. Repeated doses of the drug did not result in tolerance, drug dependency, or meaningful withdrawal effects. Among 14 classic opioid withdrawal symptoms, the researchers only observed irritability, as measured by vocalization, when handling DFNZ-treated rats. […]

    While DFNZ increases slow-acting dopamine release in the brain’s reward circuitry, it does not trigger the rapid dopamine bursts associated with the formation of strong drug-cue associations, the conditioned responses that drive craving and relapse in addiction. […]

    The research team will pursue additional preclinical studies to support an application for regulatory approval to conduct studies of DFNZ in humans. They believe several patient populations may benefit from DFNZ, including those in surgical settings and with cancer-related or chronic pain who have a particularly high need for effective pain treatment. […]

    AAAS Public Science News Release: NIH researchers discover pain-relieving drug with minimal addictive properties — Positive safety profile of novel drug compound is surprise for class of synthetic opioids shelved years ago

    Nature: A µ-opioid receptor superagonist analgesic with minimal adverse effects

    Authors: Juan L. Gomez, Emilya N. Ventriglia, Zachary J. Frangos, Agnieszka Sulima, Michael J. Robertson, Michael D. Sacco, Reece C. Budinich, Ilinca M. Giosan, Tongzhen Xie, Oscar Solis, Anna E. Tischer, Jennifer M. Bossert, Kiera E. Caldwell, Hannah Bonbrest, Amelie Essmann, Zelai M. Garçon-Poca, Shinbe Choi, Michael R. Noya, Feonil Limiac, Ali Arce, Grant C. Glatfelter, Margaret Robinson, Li Chen, Angelina A. Mullarkey, Dain R. Brademan, Garrett Enten, William Dunne, César Quiroz, Ingrid Schoenborn, Chae Bin Lee, Rana Rais, Daniel P. Holt, Robert F. Dannals, Lei Shi, Ruth Hüttenhain, Sergi Ferré, Eugene Kiyatkin, Jordi Bonaventura, Yavin Shaham, Venetia Zachariou, Michael H. Baumann, Georgios Skiniotis, Kenner C. Rice & Michael Michaelides.

  3. Servetus says:

    Psilocybin is found to be an effective treatment for obsessive compulsive disorder (OCD):

    Current treatments for obsessive–compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. […]

    Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (>35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment. […]

    Journal of Psychopharmacology: A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

    Authors: Francisco A. Moreno, Katja E. Allen, Katye E. Allen, Rajun Dunne, James I. Prickett, Brian Bayze, Christopher B. Wigand, and John J. B. Allen

  4. Servetus says:

    A study in Brazil ranked drugs according the frequency drugs were found in postmortems of homicide victims in different geographic areas:

    17-Apr-2026 — A Brazilian study based on postmortem toxicological analyses found that 53% of violent death victims had alcohol or drugs in their systems shortly after death. The study examined 3,577 cases in Belém (North), Recife (Northeast), Vitória (Southeast), and Curitiba (South), representing the four regions of the country. “The goal was to produce standardized and comparable data on the role of psychoactive substances in deaths from external causes in Brazil,” says Henrique Silva Bombana, a biomedical toxicologist, postdoctoral researcher at the University of São Paulo’s School of Pharmaceutical Sciences (FCF-USP), and the first author of the study. […]

    The profile of the victims reflects the most common face of violent mortality in the country: 89.7% were male, 56% were 30 years of age or older, and 67.3% died from homicide. This last figure is especially relevant when compared to the percentages of deaths from traffic accidents (14.7%) and suicides (9.2%). […]

    Of all the victims, 53% tested positive for at least one psychoactive substance. The most commonly detected substances were cocaine (29.6%), alcohol (27.7%), benzodiazepines (6.8%), and cannabis (2.2%). “The prevalence of cocaine was very significant in homicide cases, while alcohol was the most detected substance in traffic accident deaths. Benzodiazepines were prevalent in suicides,” reports Bombana. […]

    “The association between the substance and violent death in the case of homicide is very complicated, because we’re only looking at the victim, not the perpetrator. Still, it’s possible to attribute the high presence of cocaine not only to acute use of the substance but also to the social and economic context in which the illegal market operates – the environment of trafficking, selling, and buying that characterizes what we call structural violence,” Bombana argues.

    The presence of alcohol in traffic fatalities is a longstanding problem in the country. “The issue has been discussed for at least 30 years without a solution being found. The legislation is quite robust, but what may be lacking is greater control over the sale of alcohol. Some countries have much stricter and more restrictive rules for sales,” the researcher notes. […]

    When analyzing police records associated with homicide cases, the team found that approximately 85% of deaths were caused by gunshot wounds. “This occurred at a time when, through decrees and ordinances, the federal government at the time relaxed rules for purchasing and carrying firearms, increased limits on weapons and ammunition, expanded authorized categories, and reduced control and enforcement mechanisms – a context that helps explain the observed pattern of lethality,” Bombana emphasizes.

    The prominence of benzodiazepines in suicides raises questions about medication use, self-medication, and vulnerability. The researcher suggests a plausible hypothesis without attributing direct causality: “The use of these substances may end up serving as a trigger to transition from suicidal ideation to actual action.” […]

    Although he emphasizes that he is not a public policy specialist, Bombana argues that addressing the problem is more effective when centered on public health and harm reduction rather than repression. “Perhaps the criminalization policy, the so-called ‘war on drugs,’ isn’t the best option. Portugal decriminalized drug use and saw a decrease in the number of users, petty crimes, homicides, and overdoses. The differences between Portugal and Brazil are enormous, of course. Starting with the size of the territories and populations. Still, the Portuguese example suggests that a harm reduction policy may be the most promising path.” […]

    AAAS Public Science News Release: More than half of the victims of violent deaths in Brazil had consumed alcohol or drugs shortly before — postmortem analyses of 3,577 cases in four state capitals reveal a consistent association between psychoactive substances and homicides, accidents, and suicides, with distinct regional patterns

    Toxics: Prevalence of Psychoactive Substance Use and Violent Death: Toxicological and Geospatial Evidence from a Four-Metropolitan-Area Cross-Sectional Study in Brazil

    Authors: Henrique Silva Bombana,Vanderlei Carneiro da Silva, Ivan Dieb Miziara, Heráclito Barbosa Carvalho, Mauricio Yonamine, and Vilma Leyton.

  5. Servetus says:

    The origins of 420 written by its founders:

    CounterPunch: The Etymology of 420

  6. Servetus says:

    Kratom use with adverse medical outcomes increased from 19 in 2010 to 1,242 cases in 2023. Severe outcomes went from zero to 158:

    22-Apr-2026 – Kratom is a plant with psychoactive properties that, when taken at high doses, can produce effects similar to opioids. A new study published in Addiction has found that kratom use – measured as kratom exposures reported to US poison centers – and cases of severe medical outcomes linked to kratom use have surged in the US over the past decade.

    The study found that kratom exposures reported to America’s Poison Centers increased from 19 cases in 2010 to 1,242 cases in 2023, a more than a 65-fold (6,500%) increase.

    Kratom exposures that included severe outcomes increased from zero cases in 2010 (2012 was the first year in which a severe outcome was reported) to 158 cases in 2023. The authors of the study defined a severe medical outcome as one entailing life-threatening effects, significant residual disability, or death. […]

    Senior author Dr. Ryan Feldman, of the Medical College of Wisconsin, comments: “Kratom is not scheduled under the US Controlled Substances Act or approved for medical use by the FDA, which leaves US states to set their own regulations. Or not: several US states do not regulate kratom at all, and they consistently had worse outcomes in this study than states that banned kratom use. […]

    AAAS Public Science News Release: Kratom use is surging in the US, with life-changing consequences

  7. Servetus says:

    Coffee is good for the gut-brain axis:

    21 APR 2026 — New research from APC Microbiome Ireland, a world leading research centre at University College Cork, has comprehensively explored the mechanisms behind coffee’s positive effects on the gut-brain axis for the first time1.

    The study […] reveals how regular consumption of both caffeinated and decaffeinated coffee can affect the gut microbiome, and in turn influence mood and stress levels.

    The benefits of coffee for both digestion and mood have been widely studied, but the exact mechanisms behind these effects have remained unclear. This research investigated how coffee consumption affects the microbiota-gut-brain axis – the bidirectional communication between the gut microbiome and the brain – through a wide range of measures. […]

    Bacteria, such as ‘Eggertella sp’ or ‘Cryptobacterium curtum’, were notably increased in coffee-drinkers compared to non-coffee drinkers. The former is thought to contribute to gastric and intestinal acid secretion, while the latter is thought to be involved in bile acid synthesis – both of which may play a role in eliminating unhealthy gut bacteria and stomach infections. Increased ‘Firmicutes’ bacteria were also observed, which has been associated with positive emotions in females.

    A notable improvement in learning and memory was found only in those who consumed decaffeinated coffee, suggesting that components other than caffeine, such as polyphenols, are responsible for these cognitive benefits. However, in this study the researchers found that only caffeinated coffee was associated with reduced feelings of anxiety, as well as improved vigilance and attention. Caffeine was also linked to a reduced risk of inflammation. […]

    “Our findings reveal the microbiome and neurological responses to coffee, as well as their potential long-term benefits for a healthier microbiome. Coffee may modify what microbes do collectively, and what metabolites they use. As the public continues to think about dietary changes for the right digestive balance, coffee has the potential to also be harnessed as a further intervention as part of a healthy balanced diet”. […]

    AAAS Public Science News Release: New research reveals mechanisms behind coffee’s positive effects on the gut-brain axis

  8. Servetus says:

    Coked-up salmon like to swim:

    04 APR 26 — …cocaine and its metabolites—along with other drugs and pharmaceuticals—are widespread in the environment, mainly from human wastewater. And scientists are working to understand how such substances might affect wildlife.

    “Many aquatic organisms in human-impacted environments are living in a dilute cocktail of biologically active chemicals,” says Jack Brand, a researcher in aquatic ecology at the Swedish University of Agricultural Sciences. “We’re only really scratching the surface.”

    In the new study, Brand and his colleagues focused on wild Atlantic salmon (Salmo salar). The team fitted 105 juvenile salmon reared in captivity with an acoustic tracking tag and an implant. In one group of 35, the implant slowly released cocaine, in another it released benzoylecgonine (cocaine’s main metabolite), and in a control group it released nothing. They then released the salmon into Lake Vättern in Sweden to see what happened. […]

    Fish under the influence of benzoylecgonine swam up to 1.9 times (nearly 14 kilometers) farther on average each week compared with salmon that weren’t exposed. They also dispersed more, reaching up to about 12 kilometers farther from the release site than nonexposed fish did—a 60 percent increase.

    Benzoylecgonine had a stronger effect than cocaine itself, but the researchers aren’t completely sure why yet. “That was somewhat unexpected and has important implications because environmental risk assessments typically focus on the parent compound rather than its metabolites,” Brand says, adding that “benzoylecgonine is routinely found at higher concentrations than cocaine in aquatic environments.” […]

    But concentrations in salmon should be much lower than what would affect humans, Brand says, so you can still have a roasted fillet or a bagel with lox. […]

    Scientific American: Here’s what happens when you give salmon cocaine … it turns out that salmon exposed to cocaine through water pollution do a lot of swimming—which may not be a good thing

    Current Biology: Cocaine pollution alters the movement and space use of Atlantic salmon (Salmo salar) in a large natural lake

    Authors: Jack A. Brand, Daniel Palm1, Daniel Cerveny, Marcus Michelangeli, Aneesh P.H. Bose, Erin S. McCallum1, Gustav Hellström, Jerker Fick, Bryan W. Brooks, Tomas Brodin, Michael G. Bertram.

  9. Servetus says:

    Routine health care practices among older, healthier, wealthier people now commonly include cannabis and psychedelics:

    24-Apr-2026 — A new study by investigators from Mass General Brigham suggests that complementary health approaches (CHA)—including massage, yoga, tai chi, herbal products, acupuncture, spiritual practices, cannabis and psychedelics—are now a routine part of health and wellness for many older adults, even though they are not always discussed with healthcare providers. Using survey data from participants in the COSMOS trial, researchers found that 58% of older adults had used complementary health approaches in the last year and more than 75% had used one or more CHA in their lifetime. […]

    “Before this study, we did not know much about the characteristics of older adults who are using these complementary therapies,” said lead author Dennis Muñoz-Vergara, DVM, MPH, a researcher in the Osher Center for Integrative Health at Mass General Brigham. “This is one of the largest studies of complementary therapy use in older adults.”

    The study surveyed 16,144 participants (women over the age of 65 and men over 60) in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a large randomized, double-blind, placebo-controlled clinical trial of cocoa extract supplements and multivitamins. It’s important to note that the study group was not a perfect snapshot of older adults in the United States since participants were enrolled in a randomized clinical trial testing two dietary supplements. They were likely healthier, more engaged in health issues and had higher socioeconomic status than the broader population.

    The survey focused on six categories of complementary therapies — manual therapies, such as chiropractic care; mind-body therapies, such as tai chi; herbal products; acupuncture; spiritual practices; and the use of cannabis or psychedelics. Participants were asked whether they had ever used these therapies and then if they had used them in the past 12 months. The study did not ask why people used these therapies, how often they used them, the intensity of use, or their efficacy.

    Complementary therapy use was common in this group: 58.8 percent of respondents said they had used at least one in the past 12 months, and 76.4 percent said they had used at least one in their lives. […]

    “What surprised me most was just how common these complementary therapies were,” said Muñoz-Vergara, who was the first and corresponding author on the paper. “They are much more mainstream than many people may realize.”

    Spiritual practices were the most commonly reported approach in the past year at 38.6%, followed by manual therapies at 20.8% and herbal products at 20.5%. Acupuncture was the least commonly used at 3.7%. […]

    AAAS Public Science News Release: New research from the COSMOS trial reveals more than 75% of older adults have used complementary therapies — researchers say the finding highlights the need for more evidence and better conversations about risks and benefits of mindfulness, yoga, tai chi, acupuncture, and other complementary health approaches

    The American Journal of Medicine: Use of Complementary Health Approaches and Research Interests Among Older Adults in the COSMOS Trial

    Authors: Dennis Muñoz-Vergara, DVM; Yan Ma, MD; EunMee Yang, PhD, MPH; Sarah Jaehwa Park, ND; Wren M. Burton, DC; Eunjung Kim, MS; JoAnn E. Manson, MD, DrPH; Gloria Y. Yeh, MD; Peter M. Wayne, PhD; Howard D. Sesso, ScD, MPH.

  10. Servetus says:

    Key action items for stakeholders in the marijuana industry after rescheduling from Schedule I to Schedule III:

    Apply for DEA registration within 60 days to preserve the right to operate during agency review.

    File protective Internal Revenue Service (IRS) refund claims for prior years subject to 280E disallowance – time limits apply.

    Dual-license operators should separate medical and adult-use activities in operations and recordkeeping.

    Interstate commerce and adult-use legalization still require congressional action.

    Monitor litigation – a successful legal challenge could reinstate Schedule I obligations.

    JDSupra: Executive summary of DEA rescheduling

  11. Servetus says:

    Religious-right activist Tony Perkins of the Family Research Council is unhappy about marijuana reclassification, claiming “it is opening up our children and, of course, others to demonic activity .”

  12. Servetus says:

    Traumatic brain injury (TBI) victims are self medicating using psychedelics:

    27-Apr-2026 – A new study … has identified a segment of traumatic brain injury survivors who are using psychedelics to self-medicate for cognitive, mood and somatic symptoms such as headaches.

    In a first-of-its-kind study, clinical psychology researchers analyzed more than 6,100 responses collected from the global psychedelic survey. Researchers found that nearly 1,200 respondents reported using psychedelics to treat or manage a physical health condition.

    Of these, some 208 participants, or 3.4 per cent of the total sample, reported using psychedelics to manage brain injury-related symptoms. […]

    Some 60 million people worldwide experience traumatic brain injuries (TBI) every year. Garcia-Barrera says there isn’t a one-size-fits all treatment for TBI survivors, and he says some are looking for alternative supports, including from psychedelics.

    “Although research into using psychedelics to manage TBI symptoms remains quite limited, the field is gaining momentum as awareness grows around how widespread brain injury is globally and its impact on the quality of life of those who experience a TBI,” Garcia-Barrera says. […]

    “I wasn’t expecting so many people to be using psychedelics at this point for brain injury—it’s really new information,” says VanderZwaag. “It was surprising to find that some people globally are experimenting with this, acquiring psychedelics by themselves to see how it works for them.”

    Researchers found that respondents with TBIs most often used psilocybin every two to five months or every six months to treat their symptoms, using a mix of microdoses and larger doses. Other respondents reported self-medicating with LSD/acid and ketamine.

    Not only are people with TBIs experimenting with psychedelics to manage mood, cognitive and somatic symptoms—they are finding relief. When asked to rate how effective their psychedelic use was on their TBI-related symptoms, 90 per cent of the sample self-reported some level of symptom improvement. […]

    University of Victoria: TBI survivors turn to psychedelics for symptom relief — Study shows that patients with traumatic brain injuries are seeking alternative supports

    ScienceDirect: Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey

    Authors: Baeleigh VanderZwaag, Jill Robinson, Albert Garcia-Romeu, Mauricio Garcia-Barrera, Stephanie Lake, Philippe Lucas.

  13. Servetus says:

    40,000 public comments about marijuana reclassification were analyzed using AI:

    29-Apr-2026 — Most people strongly support the federal government’s reclassification of cannabis, according to a new study that used AI to analyze more than 40,000 comments in the public record.

    The findings by researchers at Johns Hopkins University and the University of California San Diego, which come as the Trump administration last week reclassified state-licensed medical marijuana from a Schedule I drug to a less dangerous Schedule III, suggest the public would like to see even more reform.

    “Americans showed up with their personal stories about therapy that helped them, businesses they built, consequences of cannabis use, and more,” said first author Vijay M. Tiyyala, a Johns Hopkins research assistant. […]

    The research team obtained every comment posted to the e-rulemaking portal during the 63-day comment window and used an AI-driven analysis validated against human review. Most commenters supported the change:

    63.5% supported even more reform
    28.9% supported Schedule III as proposed
    6.7% opposed any change

    Supporters of Schedule III included patients, healthcare providers, and business owners, often writing from personal experience. “This is a legit medication, it has saved my life and I’m in the medical field,” one supporter wrote. […]

    Supporters most often cited therapeutic benefits (56.7%), economic impacts on the cannabis industry and state revenues (27.8%), and the need for clearer federal regulation to ensure public safety (24.4 %).

    “Rescheduling is a meaningful first step, but the public record shows Americans want federal policy to go even further,” said senior author John W. Ayers, vice chief of innovation at UC San Diego School of Medicine.

    Commenters who said Schedule III was insufficient often called for full descheduling, which would remove the substance from federal control. “Cannabis as a whole should be descheduled in order to preserve the thousands of businesses, patients and community members that rely on the ability to grow, extract and consume cannabis,” one person wrote.

    This group cited therapeutic benefits (37.8%), economic impacts (28.6%), and criminal justice reform (26.5%). Social-justice concerns about disproportionate incarceration in marginalized communities appeared in roughly one in five of their comments.

    “Public enthusiasm for cannabis as medicine needs to be matched by federal and state investment in rigorous cannabis research,” said co-author Ryan Vandrey, a cannabis researcher at Johns Hopkins. […]

    Almost all commenters, 92.4%, wanted cannabis off Schedule I. Comments reflected 14 different types of justifications, ranging from therapeutic benefits and economic impacts to criminal justice, medical research, and comparisons with alcohol and opioids.

    “Many commenters have lived under state legalization for medical or adult use for years already. Their expectation of federal policy reflects that reality,” said co-author Johannes Thrul, an addiction researcher at Johns Hopkins. […]

    Almost all commenters, 92.4%, wanted cannabis off Schedule I. Comments reflected 14 different types of justifications, ranging from therapeutic benefits and economic impacts to criminal justice, medical research, and comparisons with alcohol and opioids.

    “Many commenters have lived under state legalization for medical or adult use for years already. Their expectation of federal policy reflects that reality,” said co-author Johannes Thrul, an addiction researcher at Johns Hopkins.

    The group opposing any change wrote most often from a public health standpoint. “Moving cannabis into a category of drugs that have a low risk of dependence gives the public false information about this drug,” one opponent wrote. Opponents cited public health risks (100%), addictiveness (71.4%), and potential harms to children and adolescents (57.1%), with parents concerned about youth access prominent among them. […]

    AAAS Public Science News Releases: Americans support cannabis rescheduling, study finds — researchers used AI to analyze comments in the public record

    Addiction: Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States

    Authors: Vijay M. Tiyyala, Cerina Dubois, Clarissa Madar, Ryan Vandrey, Johannes Thrul, Mark Dredze, John W. Ayers.

  14. Servetus says:

    Hemp microfiber-based biocomposites can replace plastic films used in packaging for agriculture and consumer products:

    28-Apr-2026 — Plastic production has expanded rapidly over recent decades, with global output reaching nearly 400 million metric tons in 2022. While plastics remain essential in packaging, agriculture, and daily consumer products, their dependence on petroleum feedstocks and the growing burden of plastic waste continue to create major environmental concerns.

    As industries search for more sustainable alternatives, plant-based biocomposites are receiving increasing attention. Among them, hemp has emerged as a promising candidate because of its low cost, biodegradability, and strong mechanical properties. However, much of the focus has traditionally been placed on hemp fibers, while hemp hurd—the inner woody core that makes up nearly half of the plant’s weight—is often treated as low-value waste or simply discarded.

    A new study published in Journal of Bioresources and Bioproducts explores how hemp hurd can be converted into microfiber-based biocomposites for packaging films and agricultural mulch films, while also evaluating their full environmental performance through life cycle assessment (LCA). […]

    AAAS Public Science News Release: Hemp waste biocomposites offer a lower-carbon alternative for packaging and agricultural films — life cycle assessment shows anaerobic digestion delivers the best environmental outcome for hemp hurd-based bioplastic systems

    Journal of Bioresources and Bioproducts: Environmental Life Cycle Assessment of Hemp Hurd-Based Biocomposites for Packaging and Mulch Film Applications

    Authors: Jhonny Alejandro Poveda-Giraldo, Hae Min Jo, Myeong Rok Ahn, June-Ho Choi, Hoyong Kim, Sunkyu Park.

  15. Servetus says:

    New compounds have been found in cannabis leaves that may have medicinal applications:

    May 1, 2026 — Scientists at Stellenbosch University (SU) have uncovered the first evidence of a rare group of phenolic compounds known as flavoalkaloids in Cannabis leaves, adding a surprising new dimension to the plant’s chemistry.

    Phenolic compounds, particularly flavonoids, are already highly valued in medicine for their antioxidant, anti-inflammatory, and anti-carcinogenic effects. This new finding suggests Cannabis may contain even more biologically important compounds than previously recognized. […]

    In their study, researchers analyzed three commercially grown Cannabis strains from South Africa and identified 79 phenolic compounds. Of these, 25 had never before been reported in Cannabis. Among them were 16 compounds tentatively classified as flavoalkaloids, a group that is rarely found in nature.

    Interestingly, these flavoalkaloids were concentrated mainly in the leaves of just one of the strains, highlighting how much chemical variation can exist between different types of Cannabis. […]

    “Most plants contain highly complex mixtures of phenolic compounds, and while flavonoids occur widely in the plant kingdom, the flavoalkaloids are very rare in nature,” she explains.

    She also notes just how chemically complex Cannabis is. “We know that Cannabis is extremely complex — it contains more than 750 metabolites — but we did not expect such high variation in phenolic profiles between only three strains, nor to detect so many compounds for the first time in the species. Especially the first evidence of flavoalkaloids in Cannabis was very exciting.” […]

    According to Prof. de Villiers, the discovery underscores how much remains to be learned about Cannabis. So far, most research has focused on cannabinoids, the compounds responsible for the plant’s psychoactive effects.

    “Our analysis again highlights the medicinal potential of Cannabis plant material, currently regarded as waste. Cannabis exhibits a rich and unique non-cannabinoid phenolic profile, which could be relevant from a biomedical research perspective,” he concludes.

    The findings suggest that even parts of the plant often discarded, such as leaves, may hold valuable compounds with potential uses in medicine. […]

    Science Daily: Don’t toss cannabis leaves: Scientists found rare compounds with medical potential — cannabis just revealed a hidden chemical treasure—rare compounds scientists never knew were there

    Journal of Chromatography A: Comprehensive two-dimensional liquid chromatographic analysis of Cannabis phenolics and first evidence of flavoalkaloids in Cannabis

    Authors: Magriet Muller, André de Villiers.

  16. Servetus says:

    Combining alcohol with cannabis edibles worsens driving impairment compared with consuming either substance alone:

    1-May-2026 — In a study supported by the National Institute on Drug Abuse of the National Institutes of Health, Johns Hopkins Medicine researchers added to evidence that using cannabis edibles and alcohol together worsens driving impairment compared with consuming either substance alone. The study also found that cannabis (alone or with alcohol) did not impair performance on standard field sobriety tests.

    These findings, published May 1 in JAMA Network, highlight the urgent need for wider public education about possible augmented effects from combining cannabis and alcohol and for improved roadside driver impairment detection methods. The study also revealed that the legal alcohol intoxication limit in most of the U.S. (0.08% breath alcohol level, or BrAC) is likely too liberal if a driver has used cannabis and alcohol together.

    “Our findings indicate that co-use of cannabis and alcohol produces significantly greater driving impairment and subjective intoxication than either substance alone,” says the study’s lead author, Austin Zamarripa, Ph.D., assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. “Importantly, these findings suggest that the interaction between cannabis edibles and alcohol is not merely additive, but may be synergistic in producing impairment, which has important implications for real-world risk.” […]

    AAAS Public Science News Release: New research shows risks of combining cannabis edibles and alcohol behind the wheel

    Author: Tory Spindle, PhD

  17. Servetus says:

    Ketamine is studied to determine its effects in treating depression:

    1-May-2026 – Weill Cornell Medicine investigators have “reverse engineered” ketamine’s antidepressant effects to identify potential new strategies for treating depression.

    While there are many effective treatments available for depression, not all patients respond to them. About one-third of patients must try multiple medications before eventually finding relief, and another third have treatment-resistant depression. An anesthetic called ketamine can provide immediate relief to some patients with treatment-resistant depression, but the effects are often short-lived. Ketamine also has serious side effects for some patients, including changes in heart rate or blood pressure, feelings of being disconnected from one’s thoughts or self and addiction. […]

    Previous studies had shown that drugs that block opioid receptors in the brain interfere with ketamine’s antidepressant effects, showing these receptors play a role in its activity. So, Dr. Liston teamed up with Dr. Joshua Levitz, a professor of biochemistry and biophysics at Weill Cornell Medicine, to identify precisely which ones were key.

    In a study published April 23 in Cell, they showed that ketamine targets a specific subset of opioid receptors on specialized brain cells called interneurons in the prefrontal cortex, a brain region that plays a central role in emotion, attention and behavior. The interneurons act as a master regulator of cell activity in this brain region, Dr. Levitz explained. But excessive stress causes these cells to become hyperactive and unduly suppress overall brain cell activity in the prefrontal cortex, contributing to depression. Ketamine can reverse this effect by stimulating the opioid receptors to tamp down the interneurons’ activity.

    “Ketamine targets these opioid receptors, relieving inhibition by the interneurons and reactivating prefrontal cortex cells for a very brief period of time—maybe only for 15 or 20 minutes,” said Dr. Levitz, who is also a professor of biochemistry in psychiatry at Weill Cornell Medicine. “That seems to be enough to kickstart this whole program of cortical reawakening.” […]

    The second study, a collaboration between the laboratories of Dr. Levitz and Dr. Francis Lee, chair of psychiatry and the Jack D. Barchas, M.D. Professor of Psychiatry at Weill Cornell Medicine, provided new insights into ketamine’s longer-term antidepressant effects. Published May 1 in Science Advances, the study confirmed in a preclinical model that cross-talk in the brain cells between a receptor called TrkB and a receptor called mGluR5 is essential to maintaining ketamine’s antidepressant effects, building on previous cell and tissue studies by the team.

    “Ketamine was always known to target different receptors, called NMDA receptors, in the brain,” said Dr. Lee, who is also psychiatrist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center. “Finding that mGluR5 receptors are involved in ketamine’s antidepressant effects is novel.”

    Previous studies have shown that ketamine and other antidepressants trigger the release of brain-derived neurotrophic factor (BDNF), a protein that promotes the survival, growth and function of brain cells. Delving deeper into the mechanism by which it exerts its effects, the team showed that BDNF stimulates the tyrosine kinase receptor TrkB and promotes interaction with the mGluR5 receptor, an interaction that strengthens connections and improves communication between brain cells.

    This interaction also leads to the removal of some of the mGluR5 receptors from the cell membrane. This prevents excessive communication between the cells from triggering a weakening of the synapses by the receptors. […]

    AAAS Public Science News Release: Reverse engineering ketamine’s effects may lead to new antidepressants

  18. Servetus says:

    A single 25-mg dose of psilocybin will cause anatomical brain changes within 60-minutes of administration with a corresponding sense of well-being lasting two-weeks to a month:

    5-May-2026 – Researchers at UC San Francisco and Imperial College London have shown that a single dose of psilocybin … causes likely anatomical brain changes that last for up to a month after the experience. 

    The study … was done in healthy volunteers who had never taken a psychedelic, but it may help explain psilocybin’s therapeutic effects on conditions like depression, anxiety, and addiction. The researchers link temporary shifts in brain “entropy” — which is the diversity of neural activity occurring in the brain — to insight. This suggests the psychedelic trip itself is important to the drug’s longer term therapeutic effects.

    The researchers found that a high dose of psilocybin led to increased entropy in the minutes and hours after taking the drug. The degree of entropy predicted how much insight, or emotional self-awareness, the participants felt the next day; and this, in turn, forecasted improvements in their sense of well-being a month later.  […]

    Within 60 minutes of taking the 25 mg dose of psilocybin, EEG revealed higher entropy, suggesting that the brain was processing a richer body of information under the psychedelic. 

    A month later, the researchers looked at their subjects’ brains with DTI, which measures the diffusion of water along neural tracts in the brain, and found that they were denser and had more integrity. This is the opposite of what happens in aging, which makes these tracts more diffuse.

    The researchers cautioned that more work needs to be done to better understand the meaning of this change, but the result is a never-before-seen sign of how psychedelics can change the brain.  […]

    The day after the 25 mg dose, all but one of the 28 subjects rated the trip as the “single most” unusual state of consciousness they had ever experienced. The remaining person rated it as among the top five.  

    The people in the study also said they had experienced more psychological insight after taking the 25 mg of psilocybin than they had after the 1 mg placebo.  

    The subjects reported increased well-being two and four weeks after the study. This was measured from responses to statements like, “I’ve been feeling optimistic about the future” and “I’ve been dealing with problems well.” A month after the study they also did better on a test of cognitive flexibility.    

    “Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” said Taylor Lyons, PhD, a research associate at Imperial College London and the first author of the paper. “The fact that these changes track with insight and improved well‑being is especially exciting.” […]

    AAAS Public Science News Release: One dose of psilocybin changes the human brain

    Nature Communications: Human brain changes after first psilocybin use

    Authors: T. Lyons, M. Spriggs, L. Kerkelä, F. E. Rosas, L. Roseman, P. A. M. Mediano, C. Timmermann, L. Oestreich, B. A. Pagni, R. J. Zeifman, A. Hampshire, W. Trender, H. M. Douglass, M. Girn, K. Godfrey, H. Kettner, F. Sharif, L. Espasiano, A. Gazzaley, M. B. Wall, D. Erritzoe, D. J. Nutt & R. L. Carhart-Harris.

  19. Servetus says:

    Despite all the drug war propaganda targeting it, marijuana is seen as the least harmful drug:

    6-May-2026 — Adolescents in California consistently perceive cannabis as less harmful than other commonly used substances, according to a new study analyzing data from two large statewide school surveys. Shu-Hong Zhu, PhD, professor at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and co-authors, examined how teens view the risks of everyday and occasional use of cannabis compared to alcohol, nicotine vapes and cigarettes, drawing on responses from more than 175,000 students across surveys conducted in 2019–2020 and 2024.

    The findings show a clear and persistent pattern: Cannabis is viewed as the least harmful substance among respondents. In the earlier survey, about two-thirds of adolescents considered regular cannabis use harmful, compared to higher proportions for alcohol, vaping and cigarettes. While perceptions of harm were lower across all substances for occasional use, cannabis remained the least concerning to teens. These trends held steady in the 2024 data, suggesting that adolescents’ relatively low perception of cannabis-related risk has remained consistent over time.

    The study also identified important differences based on age, experience and social environment. Unlike alcohol and tobacco products — where perceived harm generally stayed the same or increased with grade level — perceptions of cannabis risk declined as students got older. Younger adolescents were more likely to view cannabis as harmful, but this perception weakened significantly by 12th grade. Additionally, teens who had used a substance were less likely to view it as harmful, with the largest perception gap observed for cannabis. Peer influence played a major role as well: Adolescents with more friends who used a substance consistently rated it as less harmful, with the strongest effect again seen for cannabis. […]

    AAAS Public Science News Release: Research Alert: Teens view cannabis as less harmful than alcohol, vapes and cigarettes

    Drug and Alcohol Dependence: Adolescents view cannabis as less harmful than cigarettes, nicotine vapes, and alcohol: Findings from two California school surveys

    Authors: Deepti Agarwal, Jijiang Wang, Shuwen Li, Christopher M. Anderson, Shu-Hong Zhu.

Leave a Reply

Your email address will not be published. Required fields are marked *